Drug intelligence / Profile preview

KIN-7324

Development stage: Preclinical
Lead developer: XOMA
Modality: Small Molecules

Overview

**KIN-7324** is a preclinical small molecule inhibitor of **cyclin-dependent kinase 4 (CDK4)** developed by **Kinnate Biopharma, Inc.** for the treatment of **neoplasms**. It targets CDK4, a key regulator of the cell cycle that is frequently dysregulated in cancers, to inhibit tumor cell proliferation. The drug is in early-stage development with no reported clinical trials or approval as of the latest available data.

Targets

CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on KIN-7324.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIN-7324.

Explore the full profile